Please note: due to Russia's invasion of Ukraine, and in line with the EU position, ongoing and planned bilateral engagement between the EMCDDA and representatives of Russia and Belarus has been suspended with immediate effect.
Cooperation with EU institutions, the Reitox network (29 national drug monitoring centres), candidate and potential candidates to the EU, European Neighbourhood Policy (ENP) area countries, and regional and international organisations has been an important part of the EMCDDA’s work since its creation in 1993. This section presents the EMCDDA’s main collaborators and provides an overview of the numerous activities and projects implemented with partners worldwide. It also provides basic information on their mandates and core tasks.
Information pages on partners and cooperation
More about our partners and cooperation
EU institutions and agencies
The EMCDDA works closely with the European Union institutions and agencies. This active cooperation means that the Centre can provide constant assistance in defining a drug strategy by supplying the Member States and the Community with more reliable and comparable information. In return, the Centre’s contributions in the field of information on drugs are broadly disseminated at European level.
The EMCDDA coordinates and relies on a network of some 30 national monitoring centres (the Reitox network) to gather and analyse country data according to common data-collection standards and tools. The results of this national monitoring process are fed to the Centre for analysis and are ultimately released in the European Drug Report, Statistical Bulletin, Country Drug Reports and many other outputs.
The EMCDDA collaborates with numerous international partners, often within the framework of formal cooperation agreements supplemented by practical joint work programmes. Cooperation ranges from the exchange of information and methodologies, via ad hoc technical collaboration on specific supranational projects, to close participation in the EMCDDA’s routine data collection activities. The overall objective of this cooperation is to develop a better understanding of the changing drugs phenomenon worldwide.
The EMCDDA cooperates with candidate and potential candidates to the EU as part of their accession process to the EU, with neighbouring countries of the European Neighbourhood Policy and with other non-EU countries on the basis of bilateral agreements. Cooperation ranges from implementation of technical assistance projects to ad hoc training or consultative support. The overall objective of this cooperation is to share the EMCDDA monitoring practices, guidelines, data collection tools, and to support the countries in setting up their national drug information systems.
*Kosovo: this designation is without prejudice to positions on status, and is in line with UNSCR 1244 and the ICJ Opinion on the Kosovo declaration of independence.
*Palestine: this designation shall not be construed as recognition of a State of Palestine and is without prejudice to the individual positions of the Member States on this issue.